302917-22-2

Upstream product

• 302917-21-1 3,6-di-O-benzyl-1,2-O-isopropylidene-α-D-allofuranose 
• 100-39-0 benzyl bromide 
• 57099-04-4 3-O-benzyl-1,2-O-isopropylidene-α-D-allofuranose 

Downstream Products

• 302917-26-6 {(3aR,4R,6S,6aR)-6-[(S)-2-Benzyloxy-1-((3aR,5R,6R,6aR)-6-benzyloxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-ethoxy]-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl}-methanol 
• 302917-28-8 Methanesulfonic acid (3aR,4R,6R,6aR)-6-[(S)-2-benzyloxy-1-((3aR,5R,6R,6aR)-6-benzyloxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-ethoxy]-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl ester 
• 302917-24-4 Acetic acid (2R,3R,4R,5R)-4-acetoxy-5-acetoxymethyl-2-[(S)-2-benzyloxy-1-((3aR,5R,6R,6aR)-6-benzyloxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-ethoxy]-tetrahydro-furan-3-yl ester 

Relevant academic research and scientific papers

Functionalized nucleoside 5'-triphosphates for in vitro selection of new catalytic ribonucleic acids

A series of novel 2'-modified nucleoside 5'-triphosphates was synthesized. The amino, imidazole, and carboxylate functionalities were attached to the 5-position of pyrimidine base of these molecules through alkynyl and alkyl spacers, respectively. Two different phosphorylation methods were used to optimize the yields of these highly modified triphosphates. (C) 2000 Elsevier Science Ltd. All rights reserved.

Synthesis of the nucleoside moiety of liposidomycins: Elucidation of the pharmacophore of this family of MraY inhibitors

Tunicamycins (TCMs) and liposidomycins (LPMs) are naturally occurring inhibitors of the bacterial translocase (MraY). Based on structure-activity relationship (SAR) studies, a molecular model has been proposed for their inhibitory mechanism. This study points out the importance of the nucleoside moiety of liposidomycins in the inhibition of MraY. A simplified molecule (I) based on the liposidomycin core structure has been synthesised and tested on MraY. The compound displayed a moderate inhibitory activity (IC50 = 50 μM). The validation of the molecular model was then performed by synthesising higher homologues of I, containing an additional stereocentre in the 5' position (XIV and XV). In agreement with the prediction, only the (S) isomer XV showed significant activity against MraY (IC50 = 5 μM). (C) 2000 Elsevier Science Ltd. All rights reserved.